Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating restated by equities researchers at Noble Financial in a research report issued on Sunday.
A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday, October 20th. Aegis reiterated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a research note on Tuesday, July 18th. Oppenheimer Holdings, Inc. started coverage on Heron Therapeutics in a research note on Monday, October 30th. They issued a “buy” rating and a $27.00 price target for the company. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Northland Securities started coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $28.36.
Shares of Heron Therapeutics (NASDAQ HRTX) traded down $1.00 during mid-day trading on Friday, reaching $16.35. The company’s stock had a trading volume of 2,357,100 shares, compared to its average volume of 794,083. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $20.85. The company has a quick ratio of 2.72, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The business had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. analysts expect that Heron Therapeutics will post -3.42 EPS for the current year.
WARNING: This news story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/12/heron-therapeutics-inc-hrtx-rating-reiterated-by-noble-financial.html.
Institutional investors have recently modified their holdings of the company. Legal & General Group Plc grew its position in shares of Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,098 shares in the last quarter. Quantbot Technologies LP grew its position in shares of Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 12,024 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Heron Therapeutics during the third quarter valued at about $206,000. HighTower Advisors LLC grew its position in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Heron Therapeutics in the 1st quarter valued at about $253,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.